The first half of 2022 A shares ended. As of the close on June 30, the Shanghai Stock Exchange Index rose 1.1% to close at 3398.62 points. It rose 4.5% in the second quarter and is still down 6.63% this year. CSI 300 index rose 1.44% to 4485.01 points. It rose 6.21% in the second quarter and fell 9.22% this year.
1. The top ten bull stocks in 2022 have been released.
The top ten bull stocks in the first half of this year have also been released. According to the EQS function of the Bloomberg terminal, Zhejiang Jiancheng Investment ranked first in the return list in the first half of 2022 with a total return of 301.45%. , Huitong Group, Zhongtong Bus, and Shanghai Yizhong all increased their returns by more than 2 times, ranking second, third, and fourth respectively. Among the top ten bull stocks, 2 stocks in the infrastructure industry were shortlisted.
Note: The top ten A-share bull stocks in the first half of 2022. Source: Bloomberg terminal. As of June 30, 2022,
public information shows that Zhejiang Jiantou is currently a BT, BOT, TOT, and PPP investment company in the infrastructure field. As a leader, it is a modern enterprise group whose main business is infrastructure equity investment, asset management, facility operation, project construction and engineering management , and also takes into account government resource development, land management and other businesses.
Hualong Securities Investment Consultant Liu Wei analyzed that Zhejiang Jiantou's recent surge in stock prices is probably due to two reasons:
On the one hand, it is catalyzed by Zhejiang Jiantou's own related concepts. Zhejiang Construction Investment belongs to the infrastructure industry and is involved in previously popular concepts such as prefabricated buildings and common prosperity demonstration zones . On the other hand, it is the frequent speculation of market funds behind it. For example, "Oriental Fortune Securities Lhasa Road", known as the base camp of retail investors in the market, frequently appears on the Dragon and Tiger List of Zhejiang Construction Investment, and seats such as "Jintian Road", "Ningbo Sangtian Road" and "Stock Supporting a Family" are also listed Appear frequently.
Shanghai Yizhong is the only stock on the Science and Technology Innovation Board . Its main business is dedicated to the research and development and industrialization of improved new anti-tumor drugs. Its core product is paclitaxel polymer micelles for injection. The company's stock price has been rising since mid-April, mainly because its core product paclitaxel micelles have entered a phase of heavy volume. The product was approved at the end of October 2021 and will be officially launched on November 20. In the first quarter of this year, the company made a profit for the first time after deducting non-net profits, with revenue of 34.34 million yuan deducting non-net profits reaching 23.12 million yuan.
China’s stock market emerged from an “independent market” in the second quarter. Entering the second half of the year, domestic and foreign institutions continue to be optimistic that China’s stock market will outperform the global market.
Bloomberg’s stock market questionnaire survey of a total of 19 institutions shows that nearly 90% of institutions believe that the trend of China’s stock market performing better than other global markets will continue. The institutions' median point forecasts for the CSI 300 Index and the Hang Seng Index at the end of the year are respectively 4,690 points and 23,600 points, with 4.6% and 8% upside potential respectively from the latest closing prices.
Legend: In the first half of 2022, the CSI 300 Index outperformed the S&P Index. Source: Wind
Bloomberg News reported that the recent performance of mainland and Hong Kong stocks has attracted the attention of global investors. Among them, the CSI 300 Index outperformed the S&P in June. The 500-point increase was the largest in more than seven years.
Since the forecast price-to-earnings ratio of the CSI 300 is currently only at the average level of the past three years, and the valuation is not expensive, and the stock market is more resilient to stimulus policies and economic recovery expectations, investors have higher expectations for the performance of the Chinese stock market in the second half of the year than that of national bonds. and the RMB exchange rate market.
2. Goldman Sachs believes that Chinese stocks may become a bright spot
Goldman Sachs Group believes that Chinese stocks will become a bright spot as concerns about a global economic recession cause stocks in other developing countries to plummet.
Goldman Sachs strategists Caesar Maasry and Jolene Zhong said in a report on Friday that based on analysis of past market declines, if the United States falls into a recession, emerging market stocks could fall another 8% to 15%, which would give MSCI China index presents opportunities as improving macroeconomic indicators will boost the index's performance.
They wrote:
“Despite concerns that the U.S. may slip into recession, we expect Chinese stocks to continue to be driven by domestic economic activity and not correlate with other emerging market stocks, at least in the short term.
The MSCI Emerging Markets Index has fallen about 19% this year due to rampant inflation and central bank actions to curb it.
Goldman Sachs strategists noted that if the S&P 500 index the MSCI Emerging Markets Index would fall on average by at least 10% It fell 26%, so the current decline is not enough. The S&P 500 index is down about 20% from the high reached in January.
Editor: Lu Yifu
Coinhai Finance authorized reprint
.
